A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
2014/12/08 by Robert N. Weinreb, Robert N Weinreb, Tuyen Ong +6 · 25 citations
Medicine · #Glaucoma and retinal disorders #Ocular Surface and Contact Lens #Ophthalmology and Eye Disorders
paper · pdf · doi:10.1136/bjophthalmol-2014-305908
Abstract
AIM: To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension. METHODS: Randomised, investigator-masked, parallel-group, dose-ranging study. Subjects instilled one drop of study medication in the study eye once daily each evening for 28 days and completed five study visits. The primary efficacy endpoint was the reduction in mean diurnal IOP at Day 28. RESULTS: Of the 413 subjects randomised (LBN 0.006%, n=82; LBN 0.012%, n=85; LBN 0.024%, n=83; LBN 0.040%, n=81; latanoprost, n=82), 396 subjects completed the study. Efficacy for LBN was dose-dependent reaching a plateau at 0.024%-0.040%. LBN 0.024% led to significantly greater reductions in diurnal IOP compared with latanoprost at the primary endpoint, Day 28 (p=0.005), as well as Days 7 (p=0.033) and 14 (p=0.015). The incidence of adverse events, mostly mild and transient, was numerically higher in the LBN treatment groups compared with the latanoprost group. Hyperaemia was similar across treatments. CONCLUSIONS: LBN 0.024% dosed once daily was the lower of the two most effective concentrations evaluated, with significantly greater IOP lowering and comparable side effects relative to latanoprost 0.005%. LBN dosed once daily for 28 days was well tolerated. CLINICAL TRIAL NUMBER: NCT01223378.
Cited by
- Pharmacology and Clinical Drug Candidates in Redox Medicine. [europepmc]
- Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects. [europepmc]
- Drug discovery in ophthalmology: past success, present challenges, and future opportunities. [europepmc]
- Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. [europepmc]
- Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma. [europepmc]
- Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations. [europepmc]
- Topical treatment of glaucoma: established and emerging pharmacology. [europepmc]
- The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. [europepmc]
- Novel Therapeutics in Glaucoma Management. [europepmc]
- Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. [europepmc]
- Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. [europepmc]
- Pharmacological regulation of outflow resistance distal to Schlemm's canal. [europepmc]
- Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. [europepmc]
- Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. [europepmc]
- Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. [europepmc]
- RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis. [europepmc]
- 8 hrs Safety Evaluation Of A Multi-Pressure Dial In Eyes With Glaucoma: Prospective, Open-Label, Randomized Study. [europepmc]
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. [europepmc]
- Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study. [europepmc]
- Deconstructing aqueous humor outflow - The last 50 years. [europepmc]
- Physiologic Consequences of Caveolin-1 Ablation in Conventional Outflow Endothelia. [europepmc]
- Overnight Safety Evaluation of a Multi-Pressure Dial in Eyes with Glaucoma: Prospective, Open-Label, Randomized Study. [europepmc]
- The vital role for nitric oxide in intraocular pressure homeostasis. [europepmc]
- Cell-Matrix Interactions in the Eye: From Cornea to Choroid. [europepmc]
- Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. [europepmc]
Related